J&J raises sales forecast but keeps profit outlook unchanged; shares drop Johnson & Johnson Solid Q1 Led By A Ramp Up In Pharmaceuticals Segment Pharma fuels Johnson & Johnson's first-quarter earnings beat Remicade and Xarelto woes—and Trump pricing threats—haven't stopped Johnson & Johnson hiking its 2018 forecast Johnson & Johnson Raises Sales Outlook

J&J raises sales forecast but keeps profit outlook unchanged; shares drop

Healthcare conglomerate reported better-than-expected profit in the first quarter

Net earnings fell to $4.37 billion, or $1.60 per share, in the latest quarter, from $4.42 billion, or $1.61 per share, a year earlier. Last month, J&J reported aggressive Remicade discounting contributed to its average drug price decline of 4.6% in 2017. Questex LLC. Caruso said in a conference call with analysts and investors. Before Tuesday, the stock had fallen 5.7% for the year, while the S&P 500 has gained 0.2%.

J&J's best-selling drug Remicade (infliximab) saw its sales drop about 17% year over year in the first quarter — and an even steeper 22% decline in the U.S. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Johnson & Johnson Solid Q1 Led By A Ramp Up In Pharmaceuticals Segment

Other products came up short in the first quarter, too. Jonathan D. Pricing and competitive pressures remain a threat. Write to Jonathan D. But J&J's other drugs for immune disorders, Simponi and Stelara, compensated with sales jumps of more than 20 percent each, to a combined $1.58 billion. Oncology is J&J's second largest therapeutic area, with $2.3 billion in sales this quarter. BlackRock Inc. boosted its position in shares of Johnson & Johnson by 2.6% during the 2nd quarter.

CAPROCK Group Inc. Finally, Capital World Investors boosted its position in Johnson & Johnson by 4.1% in the second quarter. In related news, VP Paulus Stoffels sold 155,342 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. Worldwide medical devices sales increased 7.5% to $6.8 billion, consisting of an operational increase of 3.2% and a positive currency impact of 4.3%.

Pharma fuels Johnson & Johnson's first-quarter earnings beat

Biography Jonathan D. In March, J&J reported the average price paid for its medicines in the U.S. fell by 4.6% last year due to the company’s discounts. Opinion: So Long, California. Revenue from oncology drugs, including Darzalex, Imbruvica and Zytiga, rose by a combined 45 percent, to $2.31 billion. But no single product surpassed $1 billion in sales individually. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter.

CAPROCK Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after buying an additional 1,050,000 shares in the last quarter. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12.

Remicade and Xarelto woes—and Trump pricing threats—haven't stopped Johnson & Johnson hiking its 2018 forecast

Johnson & Johnson faces a litany of problems, ranging from biosimilar competition to its blockbuster Remicade to a sagging baby-care product line beset by lawsuits claiming its famous talcum powder causes cancer. But executives are clearly not concerned—at least not about J&J's short-term fortunes.

The company said it expected competition in the pharmaceutical business to continue throughout the year. The Wall Street Journal U.S. Sales from J&J's new business in pulmonary hypertension, or high blood pressure in the lungs, brought in $585 million in the quarter. The multiple myeloma drug Darzalex (daratumumab) was a bright spot for the company, growing nearly 70% this quarter to $433 million in worldwide sales.

The company reported $2.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. The firm owned 41,996 shares of the company’s stock after selling 5,123 shares during the quarter. A number of equities analysts have commented on JNJ shares. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16.

Johnson & Johnson Raises Sales Outlook

Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices.

Edition U.S. Sales of consumer products including baby items and nonprescription medicines rose 5.3 percent to $3.4 billion, led by a 10.5 percent jump in beauty products, which brought in nearly $1.1 billion. Meanwhile, management said they don't expect generic competition this year for the prostate drug Zytiga (abiraterone acetate). Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after acquiring an additional 130,437 shares in the last quarter.

Johnson & Johnson comprises about 1.2% of CAPROCK Group Inc.’s investment portfolio, making the stock its 11th biggest position. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website .

In fact, the company told investors Tuesday to expect total sales for 2018 somewhere between $81 billion and $81.8 billion, up from the $80.6 billion to $81.4 billion previously forecast. Analysts grilled Duato during the call about shortfalls for both products, which pulled in $271 million and $140 million respectively. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.

Johnson & Johnson tops 1Q views on sales spike, but net dips

Much-higher spending and one-time charges offset a12.6 percent jump in health care giant Johnson & Johnson's first-quarter revenue, trimming its profit by 1.2 percent, but the results still beat Wall Street ...

Sales of medical devices such as Acuvue contact lenses, artificial joints and surgical devices climbed 7.5 percent to nearly $6.8 billion. A cancer drug tailored to your tumor? FMR LLC boosted its position in shares of Johnson & Johnson by 5.9% during the 2nd quarter. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. A number of other institutional investors and hedge funds have also recently made changes to their positions in JNJ.

ILLEGAL ACTIVITY WARNING: “CAPROCK Group Inc. And that was after reporting first-quarter sales up 12.6% year-over-year, to $20 billion, driven largely by 19% growth in its pharmaceutical unit. J&J’s more immediate concern is its consumer business, where quarterly sales were up just 5% to $3.4 billion. The company said U.S. tax reform played a role in the increase. Sales in J&J’s pharmaceutical business jumped 19% to $9.84 billion in the first quarter while sales in its consumer and medical-devices segments rose 5.3% and 7.5%, respectively.

J&J unfazed by falling Remicade sales

BioPharma

FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after acquiring an additional 1,509,745 shares in the last quarter. The business’s revenue for the quarter was up 12.6% on a year-over-year basis. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the 2nd quarter. JNJ opened at $130.54 on Wednesday. Sells 5,123 Shares of Johnson & Johnson (NYSE:JNJ)” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette.

That's slightly better than expected, but the company acknowledged it has work to do to accelerate growth. J&J making a major pharmaceutical acquisition, indicating the company would probably rely instead on its strong pipeline of new drugs and its collaborations with other companies. Results were bolstered by foreign exchange rates, which the company said had a 4.2% positive impact. Johnson & Johnson brand first aid products arranged for a photo, in Surfside, Fla.

OLD Second National Bank of Aurora Sells 620 Shares of Johnson & Johnson (JNJ)

OLD Second National Bank of Aurora lessened its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 40,852 shares of the company’s stock after selling 620 shares during the quarter. Johnson & Johnson comprises about 2.3% […]

Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law.

One strategy it won’t be pursuing? J&J is one of the biggest health-products companies in the world by sales, and Wall Street considers its results a harbinger for the rest of the health-care industry. Overall for the quarter the company reported a profit of $4.37 billion, or $1.60 a share, down from $4.42 billion, or $1.61 a share, a year earlier. The maker of baby products, medical devices and blockbuster immune disorder drug Remicade on Tuesday reported revenue of $20.01 billion, topping analyst projections for $19.48 billion.

CAPROCK Group Inc. Sells 5123 Shares of Johnson & Johnson (NYSE:JNJ)

CAPROCK Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ) by 10.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 41,996 shares of the company’s stock after selling 5,123 shares during the quarter. Johnson & Johnson comprises about 1.2% of CAPROCK Group […]

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Like this story? A multibillion-dollar acquisition. The company upped its financial forecast for the year largely because of the performance of its pharmaceutical business, Mr. Excluding special items profit rose 13% to $2.06 a share. Sales across J&J's three business segments all posted healthy gains.

The firm owned 40,852 shares of the company’s stock after selling 620 shares during the quarter. Several analysts have recently weighed in on JNJ shares. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter.

Johnson & Johnson Earnings Just Par for the Course

Johnson & Johnson (NYSE: JNJ) reported its first quarter financial results before the markets opened on Tuesday. The company said that it had $2.06 in earnings per share (EPS) on $20.01 billion in revenue, versus consensus estimates that called for $2.00 in EPS on $19.4 billion in revenue. The same period from last year had $1.83 in EPS on $17.77 billion in revenue.

Where J&J is enjoying strong growth is in oncology, thanks largely to prostate cancer drug Zytiga and multiple myeloma drug Darzalex, which were up 62% and 69% respectively during the quarter. Caruso said. Revenue grew 13% to $20.01 billion. The New Brunswick, New Jersey, company earned net income of $4.37 billion, or $1.60 per share, down from $4.42 billion, or $1.61 per share, in 2017's first quarter.

Johnson & Johnson comprises about 2.3% of OLD Second National Bank of Aurora’s investment portfolio, making the stock its 7th biggest position. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Monday, January 22nd. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website .

The company reported $2.06 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The company said that it had $2.06 in earnings per share (EPS) on $20.01 billion in revenue. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Pricing trends continue to be a worry for investors, judging from questions analysts tossed out during the conference call.

Zytiga, Stelara Lift Johnson & Johnson's Sales

Analysts had forecast earnings of $2.02 a share on $19.46 billion in revenue. Marketing and production costs were higher partly because of the launch of its new severe psoriasis drug, Tremfya, approved last summer. The company's blockbuster rheumatoid arthritis drug Remicade brought in $1.39 billion for the quarter, slightly lower than analysts expected. A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock.

If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after acquiring an additional 130,437 shares in the last quarter. The business had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion.

But there’s no doubt the entry of biosimilars is ratcheting up pricing pressure for the top-selling Remicade. One asked executives about President Donald Trump's plan to address high drug prices in a speech next week. J&J now expects 2018 sales of $81 billion to $81.8 billion and earnings in the range of $8 to $8.20 a share. “We’re off to a strong start this year,” Mr. J&J’s shares edged down 0.9% in trading on the New York Stock Exchange.

On Monday evening, J&J announced it has inked a deal with Bristol-Myers Squibb Co. to develop and commercialize Bristol-Myers' Phase 2 Factor XIa inhibitor BMS-986177. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% in the 2nd quarter. JNJ opened at $130.54 on Wednesday. Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.